北京依生兴业科技有限公司 Yisheng Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine 2022-09-08 21:33
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from New Zealand 2021-08-09 21:00
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE 2021-07-19 09:00
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment 2020-01-06 09:00
Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors 2019-06-27 09:00
Yisheng Biopharma Announces Research Presentation of Immuno-Oncology Product at AACR Annual Meeting 2019 2019-03-28 21:00
Yisheng Biopharma Announces Clearance from China FDA to Proceed with PIKA Rabies Vaccine Clinical Study 2018-10-08 21:00
Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia 2018-07-19 21:00
The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Pancreatic Cancer Treatment 2018-02-26 22:00
Yisheng Biopharma Announces New Breakthrough Results on YS-ON-001 in Multiple Solid Tumor Experiments 2017-08-30 20:00
Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors 2017-05-01 20:00
Yisheng Biopharma to Present at BioPharma Asia Convention 2017 in Singapore 2017-03-15 20:30
US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine 2017-01-04 21:30
The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Hepatocellular Carcinoma 2016-10-24 20:00
The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Hepatocellular Carcinoma 2016-10-24 08:00
Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Positive Animal Results of Vaccine Against Ebola Virus 2016-07-15 21:52
Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 2016-01-04 09:00
1 2 3